US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
KR100361933B1
(en)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
Chemically defined nonpolymeric bonds form the platform molecule and its conjugate
|
DE4437502A1
(en)
*
|
1993-12-02 |
1995-06-08 |
Basf Ag |
Conjugates of hirudin with lipophilic cpds.
|
US5567592A
(en)
*
|
1994-02-02 |
1996-10-22 |
Regents Of The University Of California |
Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
|
RU2066551C1
(en)
*
|
1994-03-23 |
1996-09-20 |
Институт нефтехимического синтеза РАН |
Method of preparing insulin-containing polymeric hydrogel
|
WO1995032219A1
(en)
*
|
1994-05-20 |
1995-11-30 |
Hisamitsu Pharmaceutical Co., Inc. |
Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
|
US5932462A
(en)
*
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
US6251856B1
(en)
|
1995-03-17 |
2001-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
US5869602A
(en)
*
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US6004583A
(en)
*
|
1995-03-22 |
1999-12-21 |
Orex Pharmaceutical Development Corp. |
Protein-containing polymer composition for oral administration
|
CA2279669A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Enzo Therapeutics, Inc. |
Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
WO1998005362A2
(en)
*
|
1996-08-02 |
1998-02-12 |
Orex Pharmaceutical Development Corp. |
Protein-containing polymer composition for oral administration
|
US6503881B2
(en)
|
1996-08-21 |
2003-01-07 |
Micrologix Biotech Inc. |
Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
|
US6180604B1
(en)
|
1996-08-21 |
2001-01-30 |
Micrologix Biotech Inc. |
Compositions and methods for treating infections using analogues of indolicidin
|
WO1998016255A2
(en)
|
1996-10-15 |
1998-04-23 |
Navix, Inc. |
Stabilized conjugates of uncomplexed subunits of multimeric proteins
|
US6132712A
(en)
*
|
1996-12-11 |
2000-10-17 |
A. Glenn Braswell |
Superoxide dismutase stabilized with fragments of casein and pharmaceutical compositions incorporating same
|
US6416778B1
(en)
|
1997-01-24 |
2002-07-09 |
Femmepharma |
Pharmaceutical preparations and methods for their regional administration
|
US5993856A
(en)
*
|
1997-01-24 |
1999-11-30 |
Femmepharma |
Pharmaceutical preparations and methods for their administration
|
US5804183A
(en)
*
|
1997-01-31 |
1998-09-08 |
Enzon, Inc. |
Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
EP0981548A4
(en)
*
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
AU744085B2
(en)
*
|
1997-06-06 |
2002-02-14 |
Kyowa Hakko Kirin Co., Ltd. |
Chemically modified polypeptides
|
IS4518A
(en)
*
|
1997-07-09 |
1999-01-10 |
Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group |
New vaccine formulation
|
US6165458A
(en)
*
|
1997-12-26 |
2000-12-26 |
Pharmaderm Laboratories Ltd. |
Composition and method for dermal and transdermal administration of a cytokine
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
ATE466028T1
(en)
*
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
N-TERMINALLY MODIFIED GLP-1 DERIVATIVES
|
KR19990085365A
(en)
*
|
1998-05-16 |
1999-12-06 |
허영섭 |
Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
|
HU228218B1
(en)
*
|
1998-06-08 |
2013-02-28 |
Hoffmann La Roche |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
US6703381B1
(en)
*
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
NZ510689A
(en)
*
|
1998-10-16 |
2003-07-25 |
Biogen Inc |
Polymer conjugates of interferon beta-1a and uses
|
EP1121382B9
(en)
*
|
1998-10-16 |
2007-07-04 |
Biogen Idec MA Inc. |
Interferon-beta fusion proteins and uses
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
WO2000075105A1
(en)
*
|
1999-06-08 |
2000-12-14 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising aminooxy groups
|
US6209490B1
(en)
*
|
1999-06-17 |
2001-04-03 |
Gary J. Schwede |
Living quarters container for cats or ferrets
|
US6309633B1
(en)
*
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
CZ299516B6
(en)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
|
PE20010288A1
(en)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
ERYTHROPOYETIN DERIVATIVES
|
KR100345214B1
(en)
*
|
1999-08-17 |
2002-07-25 |
이강춘 |
The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
|
US6323311B1
(en)
|
1999-09-22 |
2001-11-27 |
University Of Utah Research Foundation |
Synthesis of insulin derivatives
|
CA2385533C
(en)
|
1999-10-04 |
2008-03-25 |
Shearwater Corporation |
Polymer stabilized neuropeptides
|
RU2155602C1
(en)
*
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Insulin-containing drug for oral using and method of its preparing
|
US6638906B1
(en)
*
|
1999-12-13 |
2003-10-28 |
Nobex Corporation |
Amphiphilic polymers and polypeptide conjugates comprising same
|
WO2001048052A1
(en)
|
1999-12-24 |
2001-07-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Branched polyalkylene glycols
|
AU4267700A
(en)
*
|
2000-01-13 |
2001-07-19 |
Academia Sinica |
Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
|
KR100890679B1
(en)
|
2000-02-24 |
2009-03-26 |
일라이 릴리 앤드 캄파니 |
Non-aqueous injectable formulations for extended release of somatotropin
|
CA2414076A1
(en)
|
2000-06-08 |
2001-12-13 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
MXPA03000073A
(en)
|
2000-06-26 |
2003-09-25 |
Monsanto Technology Llc |
Non-aqueous surfactant-containing formulations for extended release of somatotropin.
|
US6664234B1
(en)
|
2000-06-30 |
2003-12-16 |
Monsanto Technology Llc |
Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
|
US7105154B2
(en)
*
|
2000-07-19 |
2006-09-12 |
Pepgen Corporation |
Method of treatment using interferon-tau
|
KR20030046411A
(en)
*
|
2000-09-08 |
2003-06-12 |
그리폰 테라퓨틱스, 인코포레이티드 |
'Pseudo'-Native Chemical Ligation
|
EP1346726A4
(en)
*
|
2000-12-25 |
2004-09-15 |
Shiseido Co Ltd |
Sympathetic-activating perfume composition
|
US6867183B2
(en)
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6538104B2
(en)
*
|
2001-04-27 |
2003-03-25 |
Medical Analysis Systems, Inc. |
Stabilization of cardiac troponin I subunits and complexes
|
US20030108585A1
(en)
*
|
2001-05-04 |
2003-06-12 |
Roe R. Michael |
Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
|
EP1392339A4
(en)
*
|
2001-05-04 |
2009-05-27 |
Univ North Carolina State |
Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
|
IL158862A0
(en)
*
|
2001-05-21 |
2004-05-12 |
Nektar Therapeutics |
An insulin composition for pulmonary administration
|
WO2002096977A1
(en)
*
|
2001-05-30 |
2002-12-05 |
Nanocarrier Co., Ltd. |
Method of bonding substance to be incorporated to polymer terminal
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828305B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7008650B2
(en)
*
|
2001-08-09 |
2006-03-07 |
Lam Paul Y S |
Compositions for the treatment of acquired immunodeficiency disease
|
US6835536B2
(en)
|
2001-08-21 |
2004-12-28 |
Micrologix Biotech Inc. |
Antimicrobial cationic peptides and formulations thereof
|
AU2002328203C1
(en)
*
|
2001-08-24 |
2009-01-08 |
Migenix Inc. |
Antimicrobial and anti-inflammatory peptides
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7312192B2
(en)
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
MY127575A
(en)
*
|
2001-09-07 |
2006-12-29 |
Biocon Ltd |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US7196059B2
(en)
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
AU2002352524B2
(en)
|
2001-11-07 |
2007-10-04 |
Nektar Therapeutics |
Branched polymers and their conjugates
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
EP1455697A4
(en)
*
|
2001-12-20 |
2009-08-05 |
Femmepharma Holding Co Inc |
Vaginal delivery of drugs
|
KR20040083421A
(en)
*
|
2002-01-16 |
2004-10-01 |
펩젠 코포레이션 |
Oral administration of interferon-tau
|
ES2774801T3
(en)
|
2002-01-18 |
2020-07-22 |
Biogen Ma Inc |
Polyalkylene Polymer Compounds and Uses thereof
|
EP1513853A2
(en)
*
|
2002-05-24 |
2005-03-16 |
Neopharm, Inc. |
Cardiolipin compositions, methods of preparation and use
|
EA200401565A1
(en)
*
|
2002-05-24 |
2005-04-28 |
Неофарм, Инк. |
METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
|
AU2003236521A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
US7459435B2
(en)
*
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
AU2003270341A1
(en)
*
|
2002-09-05 |
2004-03-29 |
The General Hospital Corporation |
Modified asialo-interferons and uses thereof
|
US20050277611A1
(en)
*
|
2002-10-16 |
2005-12-15 |
Neopharm, Inc. |
Cationic cardiolipin analoges and its use thereof
|
WO2004043396A2
(en)
*
|
2002-11-09 |
2004-05-27 |
Nobex Corporation |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
US7459436B2
(en)
*
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
SG159387A1
(en)
*
|
2002-11-26 |
2010-03-30 |
Biocon Ltd In |
Modified natriuretic compounds, conjugates, and uses thereof
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
CA2509755A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US9173836B2
(en)
|
2003-01-02 |
2015-11-03 |
FemmeParma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
JP2006515026A
(en)
*
|
2003-01-02 |
2006-05-18 |
フェムファーマ ホールディング カンパニー, インコーポレイテッド |
Pharmaceutical preparations for the treatment of breast diseases and disorders
|
US7074755B2
(en)
*
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
CA2527665A1
(en)
*
|
2003-05-30 |
2004-12-16 |
Centocor, Inc. |
Formation of novel erythropoietin conjugates using transglutaminase
|
US20060078560A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Neopharm, Inc. |
Method of inducing apoptosis and inhibiting cardiolipin synthesis
|
PT2316473E
(en)
|
2003-07-23 |
2013-09-20 |
Novartis Ag |
Use of calcitonin in osteoarthritis
|
JP4880461B2
(en)
|
2003-08-13 |
2012-02-22 |
バイオコン・リミテッド |
Microparticulate fatty acid salt solid formulation for therapeutics
|
WO2005058347A1
(en)
*
|
2003-12-19 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
|
US20050136121A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Shear/Kershman Laboratories, Inc. |
Oral peptide delivery system with improved bioavailability
|
SE0401942D0
(en)
*
|
2004-07-28 |
2004-07-28 |
Lipopeptide Ab |
New antimicrobial peptide complexes
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
US8329958B2
(en)
|
2004-07-02 |
2012-12-11 |
Biocon Limited |
Combinatorial synthesis of PEG oligomer libraries
|
WO2006014673A2
(en)
|
2004-07-19 |
2006-02-09 |
Nobex Corporation |
Insulin-oligomer conjugates, formulations and uses thereof
|
EP2248531A1
(en)
|
2004-08-03 |
2010-11-10 |
Emisphere Technologies, Inc. |
Antidiabetic oral insulin-biguanide combination
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
JP2008528549A
(en)
*
|
2005-01-27 |
2008-07-31 |
ノボ ノルディスク アクティーゼルスカブ |
Insulin derivatives conjugated with structurally well-defined branched polymers
|
ES2490243T3
(en)
*
|
2005-02-02 |
2014-09-03 |
Novo Nordisk A/S |
Insulin derivatives
|
ES2361166T3
(en)
*
|
2005-07-08 |
2011-06-14 |
Biocon Limited |
INSULIN CONJUGATES.
|
WO2007011802A1
(en)
|
2005-07-18 |
2007-01-25 |
Nektar Therapeutics Al, Corporation |
Method for preparing branched functionalized polymers using branched polyol cores
|
JP5047978B2
(en)
*
|
2005-10-13 |
2012-10-10 |
バイオコン・リミテッド |
Methods for the preparation of insulin conjugates
|
ES2507098T3
(en)
|
2005-11-07 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Glucagon analogs showing physiological solubility and stability
|
RU2469709C2
(en)
|
2005-11-17 |
2012-12-20 |
Новартис Аг |
Pharmaceutical composition
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
CA2647143A1
(en)
*
|
2006-03-30 |
2007-10-11 |
Palatin Technologies, Inc. |
Cyclic natriuretic peptide constructs
|
JP2009532385A
(en)
*
|
2006-03-30 |
2009-09-10 |
パラティン・テクノロジーズ・インコーポレーテッド |
Linear natriuretic peptide construct
|
EP2015770B1
(en)
*
|
2006-05-09 |
2012-09-26 |
Novo Nordisk A/S |
Insulin derivative
|
BRPI0712559A2
(en)
|
2006-05-26 |
2012-11-20 |
Amylin Pharmaceuticals Inc |
compositions and methods for the treatment of congestive heart failure
|
GB0611405D0
(en)
*
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
EP2044097A4
(en)
*
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modified ribonucleases
|
JP2009543868A
(en)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
Methods and compositions for cancer treatment
|
ES2542146T3
(en)
*
|
2006-07-31 |
2015-07-31 |
Novo Nordisk A/S |
PEGylated extended insulin.
|
WO2008019147A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
|
BRPI0717098B8
(en)
*
|
2006-09-22 |
2021-05-25 |
Novo Nordisk As |
protease-resistant human insulin analogues, pharmaceutical composition and process for their preparation
|
US7807143B2
(en)
*
|
2006-10-18 |
2010-10-05 |
Research Development Foundation |
Alpha-MSH therapies for treatment of autoimmune disease
|
EP2104489A2
(en)
*
|
2006-12-26 |
2009-09-30 |
FemmePharma Holding Company, Inc. |
Topical administration of danazol
|
CN101578102B
(en)
*
|
2007-01-05 |
2013-07-17 |
印第安纳大学研究及科技有限公司 |
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
|
CA2677932A1
(en)
*
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
JP5496082B2
(en)
*
|
2007-04-30 |
2014-05-21 |
ノボ・ノルデイスク・エー/エス |
Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein
|
JP5628026B2
(en)
*
|
2007-06-01 |
2014-11-19 |
ノボ・ノルデイスク・エー/エス |
Stable non-aqueous pharmaceutical composition
|
US7776827B2
(en)
*
|
2007-07-27 |
2010-08-17 |
Immuneregen Biosciences, Inc. |
Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
ES2664822T3
(en)
|
2007-10-16 |
2018-04-23 |
Biocon Limited |
A solid pharmaceutical composition orally administrable and a process thereof
|
MX2010004298A
(en)
*
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity.
|
MX2010004297A
(en)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Glucagon antagonists.
|
CN101983066B
(en)
*
|
2008-01-30 |
2016-06-29 |
印第安那大学科技研究公司 |
Insulin prodrug based on ester
|
EP2254905B1
(en)
*
|
2008-03-14 |
2016-12-14 |
Novo Nordisk A/S |
Protease-stabilized insulin analogues
|
BRPI0910348B1
(en)
|
2008-03-18 |
2021-06-29 |
Novo Nordisk A/S |
INSULIN STABILIZED IN ACILLED PROTEASE, PHARMACEUTICAL COMPOSITION INCLUDING IT AND ITS USES
|
US20090271021A1
(en)
*
|
2008-04-28 |
2009-10-29 |
Popp Shane M |
Execution system for the monitoring and execution of insulin manufacture
|
AU2009260301B2
(en)
*
|
2008-06-17 |
2015-09-03 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
CA2729296A1
(en)
*
|
2008-06-17 |
2010-01-28 |
Richard D. Dimarchi |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
AU2009260302B2
(en)
|
2008-06-17 |
2014-10-23 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
BRPI0917000A2
(en)
*
|
2008-08-06 |
2016-02-16 |
Novo Nordisk Healthcare Ag |
protein conjugates with prolonged in vivo efficacy
|
US8680263B2
(en)
|
2008-09-19 |
2014-03-25 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
WO2010033220A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
EP2376520B1
(en)
|
2008-12-19 |
2014-02-12 |
Indiana University Research&Technology Corporation |
Insulin analogs
|
US8969288B2
(en)
|
2008-12-19 |
2015-03-03 |
Indiana University Research And Technology Corporation |
Amide based glucagon and superfamily peptide prodrugs
|
EP2376521B1
(en)
|
2008-12-19 |
2016-04-13 |
Indiana University Research and Technology Corporation |
Amide-based insulin prodrugs
|
MX2011007736A
(en)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds.
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
US20120046224A1
(en)
|
2009-03-12 |
2012-02-23 |
Nordic Bioscience A/S |
Treatment of diabetes and metabolic syndrome
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
US20110003000A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Femmepharma Holding Company, Inc. |
Transvaginal Delivery of Drugs
|
WO2011003633A1
(en)
|
2009-07-06 |
2011-01-13 |
Alize Pharma Ii |
Pegylated l-asparaginase
|
HUP0900482A2
(en)
|
2009-08-03 |
2011-03-28 |
Cera Med Kft |
Pharmaceutical formulation for oral administration
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
EP2488195A2
(en)
*
|
2009-10-13 |
2012-08-22 |
F. Hoffmann-La Roche AG |
Neuropeptide-2 receptor (y-2r) agonists
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
WO2011087808A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
MX2012006980A
(en)
|
2009-12-21 |
2012-07-17 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses.
|
EP2525833A2
(en)
|
2010-01-22 |
2012-11-28 |
Novo Nordisk Health Care AG |
Stable growth hormone compounds
|
TWI508737B
(en)
|
2010-01-22 |
2015-11-21 |
諾佛 儂迪克股份有限公司 |
Growth hormones with prolonged in-vivo efficacy
|
US8551946B2
(en)
|
2010-01-27 |
2013-10-08 |
Indiana University Research And Technology Corporation |
Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
RU2012153753A
(en)
|
2010-05-13 |
2014-06-20 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Glucagon superfamily peptides with activity in relation to G-protein-coupled receptors
|
US9127088B2
(en)
|
2010-05-13 |
2015-09-08 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
WO2011159895A2
(en)
|
2010-06-16 |
2011-12-22 |
Indiana University Research And Technology Corporation |
Single chain insulin agonists exhibiting high activity at the insulin receptor
|
AU2011270832B2
(en)
|
2010-06-24 |
2016-05-12 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
MX2012014576A
(en)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Amide based glucagon superfamily peptide prodrugs.
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
LT2723367T
(en)
|
2011-06-22 |
2017-08-25 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
RU2014101697A
(en)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Glucagon receptor coagonists / GLP-1
|
US20130052130A1
(en)
*
|
2011-08-30 |
2013-02-28 |
University Of Washington |
Branched Discreet PEG Constructs
|
CA2854175A1
(en)
|
2011-11-02 |
2013-05-10 |
Keybioscience Ag |
Peptide analogs for treating diseases and disorders
|
DK3095484T3
(en)
|
2011-11-02 |
2018-06-25 |
Keybioscience Ag |
CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
|
ES2672880T3
(en)
|
2011-11-17 |
2018-06-18 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides showing glucocorticoid receptor activity
|
BR112014015156A2
(en)
|
2011-12-20 |
2020-10-27 |
Indiana University Research And Technology Corporation |
ctp-based insulin analogues, their methods of production and use in the treatment of hyperglycemia, as well as nucleic acid and host cell sequences
|
US9107904B2
(en)
|
2012-04-05 |
2015-08-18 |
Massachusetts Institute Of Technology |
Immunostimulatory compositions and methods of use thereof
|
KR20150002777A
(en)
|
2012-04-11 |
2015-01-07 |
노보 노르디스크 에이/에스 |
Insulin formulations
|
CN104583232B
(en)
|
2012-06-21 |
2018-04-13 |
印第安纳大学研究及科技有限公司 |
Show the glucagon analogs of GIP receptor actives
|
CN104981251B
(en)
|
2012-09-26 |
2018-03-20 |
印第安纳大学研究及科技有限公司 |
Insulin analog dimer
|
BR112015023071A2
(en)
|
2013-03-14 |
2017-07-18 |
Univ Indiana Res & Tech Corp |
insulin-incretin conjugates
|
CN105120887A
(en)
|
2013-04-05 |
2015-12-02 |
诺和诺德保健股份有限公司 |
Growth hormone compound formulation
|
RU2015151135A
(en)
*
|
2013-04-30 |
2017-06-02 |
Массачусетс Инститьют Оф Текнолоджи |
INJECTION GEL NANO-FRAMES FOR TREATING DIABETES
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
ES2676065T3
(en)
|
2013-10-07 |
2018-07-16 |
Novo Nordisk A/S |
New derivative of an insulin analog
|
ES2713851T3
(en)
|
2013-11-14 |
2019-05-24 |
Keybioscience Ag |
Mimetics of calcitonin for the treatment of diseases and disorders
|
JP6701208B2
(en)
|
2014-09-24 |
2020-05-27 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
Lipidated amide insulin prodrug
|
JP6657230B2
(en)
|
2014-09-24 |
2020-03-04 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
Incretin-insulin conjugate
|
CA2967649A1
(en)
*
|
2014-11-21 |
2016-05-26 |
The University Of Chicago |
Synthetic peptides
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
GB201500263D0
(en)
|
2015-01-08 |
2015-02-25 |
Keybioscience Ag |
Calcitonin analogues for treating diseases and disorders
|
US9744209B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9937223B2
(en)
|
2015-01-30 |
2018-04-10 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9750785B2
(en)
|
2015-01-30 |
2017-09-05 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9687526B2
(en)
|
2015-01-30 |
2017-06-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9375478B1
(en)
|
2015-01-30 |
2016-06-28 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9925233B2
(en)
|
2015-01-30 |
2018-03-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
WO2016196017A1
(en)
|
2015-06-04 |
2016-12-08 |
Antriabio, Inc. |
Amine pegylation methods for the preparation of site-specific protein conjugates
|
JP2019515677A
(en)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
Antibody conjugates and methods of making and using the same
|
IL300839B2
(en)
|
2016-12-16 |
2024-04-01 |
Novo Nordisk As |
Insulin containing pharmaceutical compositions
|
US11806371B2
(en)
|
2017-01-19 |
2023-11-07 |
The University Of Chicago |
Oxalobacter formigenes (Of)-derived factors for the treatment of treatment/prevention of excess oxalate levels
|
GB201704429D0
(en)
|
2017-03-21 |
2017-05-03 |
Keybioscience Ag |
Calcitonin mimetics for treating diseases and disorders
|
GB201707955D0
(en)
|
2017-05-18 |
2017-07-05 |
Keybioscience Ag |
Dual amylin and calcitonin receptor agonists for treating diseases and disorders
|
US10174302B1
(en)
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
GB201813678D0
(en)
|
2018-08-22 |
2018-10-03 |
Keybioscience Ag |
Acylated calcitonin mimetics
|
GB201813677D0
(en)
|
2018-08-22 |
2018-10-03 |
Keybioscience Ag |
Calcitonin mimetics for treating diseases and disorders
|